Bayn Europe AB strengthens product industrialisation through cooperation with Jemedic AB

Report this content

Bayn enters into a cooperation with Jemedic AB who is specialised in contract manufacturing of tasty chewable tablets and lozenges. 

In this strategic cooperation Bayn’s innovation and formula development enters into industrialisation of tablet and lozenges and provides the market with a total solution. Doing this shortens the lab to market process, giving Bayn a great opportunity to generate new revenue faster.

“We are very pleased about this cooperation which enables Bayn to industrialise and produce our formulas of tablets and lozenges for the market and to generate revenue. The cooperation provides opportunities for finished products which can directly serve the market with the highest quality standard and competitive advantages in this product area around the world”, says Lucy Dahlgren, CEO at Bayn.

“Bayn is a specialist in natural sweetening solutions and sensory analysis. We are delighted to work with Bayn’s specialist in the new formula and product development. This cooperation will create business value for both of us”, says Lars Jern, CEO at Jemedic.

For more information, please contact Lucy Dahlgren, CEO, Bayn Europe AB, e-mail ld@bayn.se

About Bayn:

Bayn Europe is a Swedish knowledge and innovation company helping food producers around the world to find new business opportunities and surpass competition. Bayn’s solutions reduce sugar in products and create new naturally sweetened products with less calories. They are based on natural origin sweeteners, scientific research and creative recipes. Bayn is listed at Nasdaq Stockholm, First North, under the short name BAYN.

Mangold Fondkommission AB is the company Certified Adviser, phone. +46 8 5030 1550

For more information, see www.bayn.se.

About Jemedic:

Jemedic is a Swedish contract manufacturing pharmaceutical company with a substancial experience in the industry. They develop and manufacture soft and tasty chewable tablets and lozenges. Jemedic is market leading in this field. The company was founded in 1995 and was with this method one of the first in the world to manufacture pharmaceutical pastilles under GMP* conditions.

For more information, see www.jemedic.se

*GMP; Good Manufacturing Practice

Taggar:

Prenumerera